002317 众生药业
已收盘 07-03 15:00:00
资讯
新帖
简况
众生药业最新公告：控股子公司获得欧洲专利证书
证券之星 · 07-02 18:10
众生药业最新公告：控股子公司获得欧洲专利证书
众生药业(002317.SZ)获得瑞巴派特片药品注册证书
智通财经 · 06-28
众生药业(002317.SZ)获得瑞巴派特片药品注册证书
众生药业最新公告：全资子公司获瑞巴派特片《药品注册证书》
证券之星 · 06-28
众生药业最新公告：全资子公司获瑞巴派特片《药品注册证书》
众生药业（002317）股东张玉立质押798.2万股，占总股本0.94%
证券之星 · 06-20
众生药业（002317）股东张玉立质押798.2万股，占总股本0.94%
众生药业(002317.SZ)拟推2024年员工持股计划
智通财经 · 06-14
众生药业(002317.SZ)拟推2024年员工持股计划
众生药业最新公告：子公司获得地夸磷索钠化学原料药上市申请批准通知书
证券之星 · 06-13
众生药业最新公告：子公司获得地夸磷索钠化学原料药上市申请批准通知书
众生药业(002317.SZ)：地夸磷索钠化学原料药上市申请获批
智通财经 · 06-13
众生药业(002317.SZ)：地夸磷索钠化学原料药上市申请获批
涉50亿元特大虚开发票案？众生药业：没有应披露未披露事项
中新经纬 · 06-13
涉50亿元特大虚开发票案？众生药业：没有应披露未披露事项
众生药业(002317.SZ)董事长、总裁陈永红完成增持20.24万股
智通财经 · 06-07
众生药业(002317.SZ)董事长、总裁陈永红完成增持20.24万股
众生药业：公司综合考虑经营管理、生产规划、研发战略等因素，跟市场主体开展合作
证券之星 · 06-07
众生药业：公司综合考虑经营管理、生产规划、研发战略等因素，跟市场主体开展合作
众生药业最新公告：全资子公司获得普拉洛芬滴眼液《药品注册证书》
证券之星 · 05-27
众生药业最新公告：全资子公司获得普拉洛芬滴眼液《药品注册证书》
众生药业(002317.SZ)子公司获得普拉洛芬滴眼液药品注册证书
智通财经 · 05-27
众生药业(002317.SZ)子公司获得普拉洛芬滴眼液药品注册证书
众生药业(002317.SZ)2023年度每10股派2元 股权登记日为5月22日
智通财经 · 05-16
众生药业(002317.SZ)2023年度每10股派2元 股权登记日为5月22日
众生药业：4月30日高管陈永红增持股份合计4000股
证券之星 · 05-06
众生药业：4月30日高管陈永红增持股份合计4000股
众生药业：4月26日高管陈永红增持股份合计4.28万股
证券之星 · 04-29
众生药业：4月26日高管陈永红增持股份合计4.28万股
众生药业：4月25日高管陈永红增持股份合计3.56万股
证券之星 · 04-26
众生药业：4月25日高管陈永红增持股份合计3.56万股
众生药业：4月24日高管陈永红增持股份合计2万股
证券之星 · 04-25
众生药业：4月24日高管陈永红增持股份合计2万股
众生药业：主要是报告期内确认预计退货所致
证券之星 · 04-24
众生药业：主要是报告期内确认预计退货所致
众生药业(002317)3月31日股东户数9.4万户，较上期减少11.72%
证券之星 · 04-23
众生药业(002317)3月31日股东户数9.4万户，较上期减少11.72%
图解众生药业一季报：第一季度单季净利润同比减63.20%
证券之星 · 04-23
图解众生药业一季报：第一季度单季净利润同比减63.20%
暂无数据
公司概况
公司名称：
广东众生药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-12-11
主营业务：
广东众生药业股份有限公司主营业务是药品研发、生产、销售。公司主要产品有复方血栓通系列产品、众生丸系列产品、头孢克肟分散片、头孢拉定胶囊、硫糖铝口服混悬液。公司为高新技术企业。公司入选“2022中国医药创新企业100强”、“2021年度中国医药工业百强”、“2022年广东省制造业企业500强”。
发行价格：
55.00
{"stockData":{"symbol":"002317","market":"SZ","secType":"STK","nameCN":"众生药业","latestPrice":11.28,"timestamp":1719990207000,"preClose":11.45,"halted":0,"volume":8832154,"delay":0,"floatShares":762000000,"shares":852999999,"eps":0.2053,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.17,"latestTime":"07-03 15:00:00","open":11.45,"high":11.47,"low":11.22,"amount":99975500,"amplitude":0.0218,"askPrice":11.29,"askSize":136,"bidPrice":11.28,"bidSize":944,"shortable":0,"etf":0,"ttmEps":0.2053,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720056600000},"adr":0,"adjPreClose":11.45,"symbolType":"stock","openAndCloseTimeList":[[1719970200000,1719977400000],[1719982800000,1719990000000]],"highLimit":12.6,"lowLimit":10.31,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":853350477,"pbRate":2.22,"roa":"--","roe":"1.17%","epsLYR":0.32,"committee":0.257152,"marketValue":9626000000,"floatMarketCap":8593000000,"peRate":54.943984,"changeRate":-0.0148,"turnoverRate":0.0116,"status":1},"requestUrl":"/m/hq/s/002317/tweets","defaultTab":"tweets","newsList":[{"id":"2448139549","title":"众生药业最新公告：控股子公司获得欧洲专利证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2448139549","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448139549?lang=zh_cn&edition=full","pubTime":"2024-07-02 18:10","pubTimestamp":1719915056,"startTime":"0","endTime":"0","summary":"众生药业公告，公司控股子公司众生睿创收到欧洲专利局颁发的专利证书，发明名称为作为PPAR激动剂的吡咯烷衍生物的无定形及其制备方法。专利权人为广东众生睿创生物科技有限公司。本次专利授权不会对公司短期的财务状况、经营业绩构成重大影响。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070200028319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","002317","BK0188"],"gpt_icon":0},{"id":"2446501557","title":"众生药业(002317.SZ)获得瑞巴派特片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2446501557","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446501557?lang=zh_cn&edition=full","pubTime":"2024-06-28 20:16","pubTimestamp":1719577018,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业(002317.SZ)发布公告，公司全资子公司广东华南药业集团有限公司于近日收到国家药品监督管理局核准签发的瑞巴派特片《药品注册证书》。瑞巴派特片是一种胃黏膜保护剂，具有保护胃黏膜及促进溃疡愈合的作用。瑞巴派特片为医保目录乙类药物，临床用于急性胃炎、慢性胃炎的急性加重期胃黏膜病变(糜烂、出血、充血、水肿)的改善，以及用于胃溃疡的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0077","BK0188","002317"],"gpt_icon":0},{"id":"2446506567","title":"众生药业最新公告：全资子公司获瑞巴派特片《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2446506567","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446506567?lang=zh_cn&edition=full","pubTime":"2024-06-28 19:40","pubTimestamp":1719574838,"startTime":"0","endTime":"0","summary":"众生药业公告，全资子公司广东华南药业集团有限公司于近日收到国家药品监督管理局核准签发的瑞巴派特片《药品注册证书》。瑞巴派特片是一种胃黏膜保护剂，具有保护胃黏膜及促进溃疡愈合的作用。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062800046467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0188","BK0077"],"gpt_icon":0},{"id":"2444214562","title":"众生药业（002317）股东张玉立质押798.2万股，占总股本0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2444214562","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444214562?lang=zh_cn&edition=full","pubTime":"2024-06-20 21:25","pubTimestamp":1718889932,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业6月20日公开信息显示，股东张玉立向华泰证券(上海)资产管理有限公司合计质押798.2万股，占总股本0.94%。质押详情见下表：截止本公告日，股东张玉冲已累计质押股份1119.0万股，占其持股总数的12.08%，股东张玉立已累计质押股份1559.2万股，占其持股总数的16.83%。众生药业主营业务：药品研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062000040879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","002317"],"gpt_icon":0},{"id":"2443251066","title":"众生药业(002317.SZ)拟推2024年员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2443251066","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443251066?lang=zh_cn&edition=full","pubTime":"2024-06-14 19:28","pubTimestamp":1718364498,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业(002317.SZ)发布2024年员工持股计划(草案)，拟筹集资金总额不超过人民币3708.068万元，以“份”作为认购单位，每份份额为1.00元，员工持股计划的份数上限为3708.068万份。持股计划涉及的标的股票规模不超过555.10万股，占公司当前总股本的0.65%。持股计划(含预留份额)购买公司回购股份的价格为6.68元/股，为本员工持股计划草案公告前20个交易日公司股票交易均价的50%。此次员工持股计划的存续期为60个月，自本员工持股计划草案经公司股东大会审议通过且公司公告最后一笔标的股票过户至本员工持股计划名下之日起算。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1135675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002317","BK0188","BK0239","BK0077"],"gpt_icon":0},{"id":"2443089502","title":"众生药业最新公告：子公司获得地夸磷索钠化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2443089502","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443089502?lang=zh_cn&edition=full","pubTime":"2024-06-13 19:51","pubTimestamp":1718279466,"startTime":"0","endTime":"0","summary":"众生药业公告，全资子公司广东先强药业有限公司于近日收到国家药品监督管理局核准签发的原料药地夸磷索钠《化学原料药上市申请批准通知书》。地夸磷索钠是一种P2Y2受体激动剂，其滴眼液制剂用于干眼症的治疗。地夸磷索钠作用于结膜上皮及杯状细胞膜上的P2Y2受体，通过上调细胞内的钙离子浓度，促进水分及黏蛋白的分泌，进而改善干眼病症状。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061300036870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","002317","BK0188"],"gpt_icon":0},{"id":"2443501169","title":"众生药业(002317.SZ)：地夸磷索钠化学原料药上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2443501169","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443501169?lang=zh_cn&edition=full","pubTime":"2024-06-13 19:20","pubTimestamp":1718277621,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业 发布公告，公司全资子公司广东先强药业有限公司于近日收到国家药品监督管理局核准签发的原料药地夸磷索钠《化学原料药上市申请批准通知书》。本次地夸磷索钠原料药获得《化学原料药上市申请批准通知书》，表明该原料药已符合国家相关药品审评技术标准，已批准可在国内制剂中使用和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1134998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","002317","BK0239","BK0077"],"gpt_icon":0},{"id":"2443522211","title":"涉50亿元特大虚开发票案？众生药业：没有应披露未披露事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2443522211","media":"中新经纬","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443522211?lang=zh_cn&edition=full","pubTime":"2024-06-13 12:50","pubTimestamp":1718254211,"startTime":"0","endTime":"0","summary":"(王玉玲)近日，据平安乌兰浩特(乌兰浩特市公安局)微信公众号，办案民警日前侦破一...","market":"us","thumbnail":"http://www.jwview.com/jingwei/06-13/U832P902T1D596066F10DT20240613125011.jpg","type":0,"news_type":0,"thumbnails":["http://www.jwview.com/jingwei/06-13/U832P902T1D596066F10DT20240613125011.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.jwview.com/jingwei/html/06-13/596066.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zxjw_stock","symbols":["BK0077","BK0239","002317","BK0188"],"gpt_icon":0},{"id":"2441003026","title":"众生药业(002317.SZ)董事长、总裁陈永红完成增持20.24万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2441003026","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441003026?lang=zh_cn&edition=full","pubTime":"2024-06-07 17:41","pubTimestamp":1717753303,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业(002317.SZ)公告，公司董事长、总裁陈永红通过深圳证券交易所交易系统以集中竞价交易方式累计增持公司股票20.24万股，累计增持金额301.28万元(不含交易费用)，本次增持计划实施期限届满并已实施完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1132794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0188","002317","BK0077"],"gpt_icon":0},{"id":"2441032741","title":"众生药业：公司综合考虑经营管理、生产规划、研发战略等因素，跟市场主体开展合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2441032741","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441032741?lang=zh_cn&edition=full","pubTime":"2024-06-07 17:03","pubTimestamp":1717750992,"startTime":"0","endTime":"0","summary":"公司综合考虑经营管理、生产规划、研发战略等因素，跟市场主体开展合作。该案为未决诉讼，公司不服一审判决，认为一审判决存在不合理性，公司将按照司法程序提起上诉，以维护公司合法权益。2014年，公司与上海沃立生物科技有限公司就普拉洛芬滴眼液达成合作并签订了为期10年的《普拉洛芬滴眼液生产合作协议》），约定普拉洛芬滴眼液上市后由公司负责生产，沃立生物负责市场推广及销售，双方共享合作产品收益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060700033292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","002317"],"gpt_icon":0},{"id":"2438007408","title":"众生药业最新公告：全资子公司获得普拉洛芬滴眼液《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2438007408","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438007408?lang=zh_cn&edition=full","pubTime":"2024-05-27 18:49","pubTimestamp":1716806983,"startTime":"0","endTime":"0","summary":"众生药业公告，全资子公司广东华南药业集团有限公司于近日收到国家药品监督管理局核准签发的普拉洛芬滴眼液《药品注册证书》。普拉洛芬滴眼液适应症为外眼及眼前节炎症的对症治疗（眼睑炎、结膜炎、角膜炎、巩膜炎、浅层巩膜炎、虹膜睫状体炎、术后炎症）。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052700022568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0188","002317"],"gpt_icon":0},{"id":"2438005648","title":"众生药业(002317.SZ)子公司获得普拉洛芬滴眼液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2438005648","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438005648?lang=zh_cn&edition=full","pubTime":"2024-05-27 18:46","pubTimestamp":1716806806,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业(002317.SZ)发布公告，公司全资子公司广东华南药业集团有限公司于近日收到国家药品监督管理局核准签发的普拉洛芬滴眼液《药品注册证书》。此次公司产品普拉洛芬滴眼液以化学药品注册分类4类获批上市，标志着此产品视同通过化学仿制药一致性评价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1126607.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002317","BK0239","BK0188","BK0077"],"gpt_icon":0},{"id":"2435967357","title":"众生药业(002317.SZ)2023年度每10股派2元 股权登记日为5月22日","url":"https://stock-news.laohu8.com/highlight/detail?id=2435967357","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435967357?lang=zh_cn&edition=full","pubTime":"2024-05-16 18:50","pubTimestamp":1715856627,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业(002317.SZ)发布公告，公司将实施2023年年度权益分派，向全体股东每10股派发现金红利2元(含税)，股权登记日为5月22日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1122136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","002317","BK0239","BK0188"],"gpt_icon":0},{"id":"2433473769","title":"众生药业：4月30日高管陈永红增持股份合计4000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433473769","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433473769?lang=zh_cn&edition=full","pubTime":"2024-05-06 21:01","pubTimestamp":1715000468,"startTime":"0","endTime":"0","summary":"证券之星消息，根据5月6日市场公开信息、上市公司公告及交易所披露数据整理，众生药业最新董监高及相关人员股份变动情况：2024年4月30日公司董事,高管陈永红共增持公司股份4000.0股，占公司总股本为0.0005%。众生药业近半年内的董监高及核心技术人员增减持详情如下：众生药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入1576.76万，融资余额增加；融券净流入10.43万，融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600026380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0188","BK0239","BK0077"],"gpt_icon":0},{"id":"2431857169","title":"众生药业：4月26日高管陈永红增持股份合计4.28万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431857169","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431857169?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:01","pubTimestamp":1714395674,"startTime":"0","endTime":"0","summary":"证券之星消息，根据4月29日市场公开信息、上市公司公告及交易所披露数据整理，众生药业最新董监高及相关人员股份变动情况：2024年4月26日公司董事,高管陈永红共增持公司股份4.28万股，占公司总股本为0.005%。众生药业近半年内的董监高及核心技术人员增减持详情如下：众生药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出151.66万，融资余额减少；融券净流入3.58万，融券余额增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900030914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002317","BK0077"],"gpt_icon":0},{"id":"2430274019","title":"众生药业：4月25日高管陈永红增持股份合计3.56万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430274019","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430274019?lang=zh_cn&edition=full","pubTime":"2024-04-26 21:03","pubTimestamp":1714136637,"startTime":"0","endTime":"0","summary":"证券之星消息，根据4月26日市场公开信息、上市公司公告及交易所披露数据整理，众生药业最新董监高及相关人员股份变动情况：2024年4月25日公司董事,高管陈永红共增持公司股份3.56万股，占公司总股本为0.0042%。众生药业近半年内的董监高及核心技术人员增减持详情如下：众生药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入910.94万，融资余额增加；融券净流入3.04万，融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600053438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0077","002317"],"gpt_icon":0},{"id":"2430838372","title":"众生药业：4月24日高管陈永红增持股份合计2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430838372","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430838372?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:01","pubTimestamp":1714050076,"startTime":"0","endTime":"0","summary":"证券之星消息，根据4月25日市场公开信息、上市公司公告及交易所披露数据整理，众生药业最新董监高及相关人员股份变动情况：2024年4月24日公司董事,高管陈永红共增持公司股份2.0万股，占公司总股本为0.0023%。众生药业近半年内的董监高及核心技术人员增减持详情如下：众生药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出832.42万，融资余额减少；融券净流入2.77万，融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500044202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002317","BK0239","BK0077"],"gpt_icon":0},{"id":"2429744439","title":"众生药业：主要是报告期内确认预计退货所致","url":"https://stock-news.laohu8.com/highlight/detail?id=2429744439","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429744439?lang=zh_cn&edition=full","pubTime":"2024-04-24 19:01","pubTimestamp":1713956497,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)04月24日在投资者关系平台上答复投资者关心的问题。投资者：公司公布的年报当中，众生睿创营业收入5700多万，但是在你半年报时，公司公布的众生睿创的营收是7500多万，怎么回事？众生药业董秘：您好！主要是报告期内确认预计退货所致。谢谢！以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400039247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002317","BK0239","BK0188"],"gpt_icon":0},{"id":"2429165917","title":"众生药业(002317)3月31日股东户数9.4万户，较上期减少11.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429165917","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429165917?lang=zh_cn&edition=full","pubTime":"2024-04-23 17:07","pubTimestamp":1713863244,"startTime":"0","endTime":"0","summary":"证券之星消息，近日众生药业披露，截至2024年3月31日公司股东户数为9.4万户，较12月31日减少1.25万户，减幅为11.72%。在中药行业个股中，众生药业股东户数高于行业平均水平，截至3月31日，中药行业平均股东户数为5.19万户。从股价来看，2023年12月31日至2024年3月31日，众生药业区间跌幅为0.5%，在此期间股东户数减少1.25万户，减幅为11.72%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300032961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0239","002317"],"gpt_icon":0},{"id":"2429686972","title":"图解众生药业一季报：第一季度单季净利润同比减63.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429686972","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429686972?lang=zh_cn&edition=full","pubTime":"2024-04-23 01:48","pubTimestamp":1713808127,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业2024年一季报显示，公司主营收入6.41亿元，同比下降14.15%；归母净利润5129.39万元，同比下降63.2%；扣非净利润7222.69万元，同比下降43.58%；负债率26.46%，投资收益716.81万元，财务费用223.02万元，毛利率56.49%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300002250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2009-12-11","address":"广东省东莞市石龙镇西湖工业区信息产业园","stockEarnings":[{"period":"1week","weight":0.0133},{"period":"1month","weight":-0.1384},{"period":"3month","weight":-0.2543},{"period":"6month","weight":-0.2585},{"period":"1year","weight":-0.3174},{"period":"ytd","weight":-0.2766}],"companyName":"广东众生药业股份有限公司","boardCode":"AI0027","perCapita":"8102股","boardName":"医药制造业","registeredCapital":"85335万元","compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":-0.0291},{"period":"3month","weight":-0.0236},{"period":"6month","weight":0.0144},{"period":"1year","weight":-0.0761},{"period":"ytd","weight":0.0074}],"survey":" 广东众生药业股份有限公司主营业务是药品研发、生产、销售。公司主要产品有复方血栓通系列产品、众生丸系列产品、头孢克肟分散片、头孢拉定胶囊、硫糖铝口服混悬液。公司为高新技术企业。公司入选“2022中国医药创新企业100强”、“2021年度中国医药工业百强”、“2022年广东省制造业企业500强”。","serverTime":1720020576422,"listedPrice":55,"stockholders":"94019人(较上一季度减少11.72%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"众生药业,002317,众生药业股票,众生药业股票老虎,众生药业股票老虎国际,众生药业行情,众生药业股票行情,众生药业股价,众生药业股市,众生药业股票价格,众生药业股票交易,众生药业股票购买,众生药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}